Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – November 10, 2021 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call - Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_6TXBx4LyQl263HBaubdWkQ
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 995 8131 2722
Passcode: 71209450

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. October 13, 2021 DUR Board Meeting Minutes
   B. October 13, 2021 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. Chandler, Dr. Ha, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/U.S. Food and Drug Administration (FDA) Safety Alerts – See Appendix B**
   A. Pharmacy Helpdesk Activity for October 2021
   B. Medication Coverage Activity for October 2021
   C. FDA Safety Alerts

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

5. **Action Item – 2022 DUR Board Meeting Dates – See Appendix C**

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Jakafi® (Ruxolitinib) and Rezurock™ (Belumosudil) – See Appendix D**
   A. Market News and Updates
   B. Jakafi® (Ruxolitinib) Product Summary
   C. Rezurock™ (Belumosudil) Product Summary
   D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Bylvay™ (Odevixibat) – See Appendix E**
   A. Market News and Updates
   B. Bylvay™ (Odevixibat) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Lupkynis™ (Voclosporin) and Saphnelo™ (Anifrolumab-fnia) and Update the Approval Criteria for the Targeted Immunomodulator Agents – See Appendix F**
   A. Market News and Updates
   B. Lupkynis™ (Voclosporin) Product Summary
   C. Saphnelo™ (Anifrolumab-fnia) Product Summary
   D. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

9. **Action Item – Annual Review of Botulinum Toxins – See Appendix G**
   A. Current Prior Authorization Criteria
   B. Utilization of Botulinum Toxins
   C. Prior Authorization of Botulinum Toxins
   D. Market News and Updates
   E. College of Pharmacy Recommendations
   F. Utilization Details of Botulinum Toxins

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. **Action Item – Annual Review of Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications – See Appendix H**
    A. Current Prior Authorization Criteria
    B. Utilization of Asthma and COPD Maintenance Medications
    C. Prior Authorizations of Asthma and COPD Maintenance Medications
    D. Market News Updates
    E. Nucala (Mepolizumab) Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Product Summary
    F. Xolair® (Omalizumab) Nasal Polyps Product Summary
    G. College of Pharmacy Recommendations
    H. Utilization Details of Asthma and COPD Maintenance Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

11. **Action Item – Annual Review of Carbaglu® (Carglumic Acid) – See Appendix I**
    A. Current Prior Authorization Criteria
    B. Utilization of Carbaglu® (Carglumic Acid)
    C. Prior Authorization of Carbaglu® (Carglumic Acid)
    D. Market News and Updates

E. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

12. Annual Review of Multiple Myeloma Medications and 30-Day Notice to Prior Authorize Abecma® (Idecabtagene Vicleucel), Farydak® (Panobinostat), and Pepaxto® (Melphalan Flufenamide) – See Appendix J

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Multiple Myeloma Medications
D. Prior Authorization of Multiple Myeloma Medications
E. Market News and Updates
F. Abecma® (Idecabtagene Vicleucel) Product Summary
G. Farydak® (Panobinostat) Product Summary
H. Pepaxto® (Melphalan Flufenamide) Product Summary
I. College of Pharmacy Recommendations
J. Utilization Details of Multiple Myeloma Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

13. Annual Review of Lenvima® (Lenvatinib) and 30-Day Notice to Prior Authorize Jemperli® (Dostarlimab-gxly) – See Appendix K

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Lenvima® (Lenvatinib)
D. Prior Authorization of Lenvima® (Lenvatinib)
E. Market News and Updates
F. Jemperli® (Dostarlimab-gxly) Product Summary
G. College of Pharmacy Recommendations
H. Utilization Details of Lenvima® (Lenvatinib)

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

14. Annual Review of Atopic Dermatitis (AD) Medications and 30-Day Notice to Prior Authorize Opzelura™ (Ruxolitinib 1.5% Cream) – See Appendix L

A. Current Prior Authorization Criteria
B. Utilization of AD Medications
C. Prior Authorization of AD Medications
D. Market News and Updates
E. Opzelura™ (Ruxolitinib 1.5% Cream) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of AD Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

15. Annual Review of Mycapssa® (Octreotide) and Signifor® LAR (Pasireotide) – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of Mycapssa® (Octreotide) and Signifor® LAR (Pasireotide)

C. Prior Authorization of Mycapssa® (Octreotide) and Signifor® LAR (Pasireotide)
D. Market News and Updates
E. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)

A. Anticoagulants and Platelet Aggregation Inhibitors
B. Antidepressants
C. Crohn's Disease and Ulcerative Colitis (UC) Medications
D. Skin Cancer Medications

*Future product and class reviews subject to change.

18. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.